Efficacy and safety of sequential versus quadruple therapy as second-line treatment for helicobacter pylori infection-A randomized controlled trial

Daniela Munteanu, Ohad Etzion, Gil Ben-Yakov, Daniel Halperin, Leslie Eidelman, Doron Schwartz, Victor Novack, Naim Abufreha, Pavel Krugliak, Alexander Rozenthal, Nava Gaspar, Alexander Moshkalo, Vitaly Dizingof, Alexander Fich, Daniela Munteanu, Ohad Etzion, Gil Ben-Yakov, Daniel Halperin, Leslie Eidelman, Doron Schwartz, Victor Novack, Naim Abufreha, Pavel Krugliak, Alexander Rozenthal, Nava Gaspar, Alexander Moshkalo, Vitaly Dizingof, Alexander Fich

Abstract

Background and aims: Quadruple therapy is recommended as second-line treatment for Helicobacter pylori eradication failure. However, high cost, multiple side effects, and low adherence rates are major drawbacks to its routine use. Our aim was to compare the efficacy and safety of sequential versus quadruple regimens as second line treatment for persistent Helicobacter pylori infection.

Methods: Prospective, randomized, open label trial was conducted at a large academic, tertiary care center in Israel. Patients who previously failed a standard triple treatment eradication course were randomly assigned (1:1) to receive a 10-day sequential therapy course, or a 14-day quadruple regimen. Compliance and adverse events were evaluated by telephone questionnaires. The primary endpoint for analysis was the rate of Helicobacter pylori eradication as defined by either a negative 13C-urea breath-test, or stool antigen test, 4-16 weeks after treatment assessed under the non-inferiority hypothesis. The trial was terminated prematurely due to low recruitment rates. See S1 Checklist for CONSORT checklist.

Results: One hundred and one patients were randomized. Per modified intention-to-treat analysis, eradication rate was 49% in the sequential versus 42.5% in the quadruple regimen group (p-value for non-inferiority 0.02). Forty-two (84.0%) versus 33 (64.7%) patients completed treatment in the sequential and quadruple groups respectively (p 0.027). Gastrointestinal side effects were more common in the quadruple regimen group.

Conclusion: Sequential treatment when used as a second line regimen, was non-inferior to the standard of care quadruple regimen in achieving Helicobacter pylori eradication, and was associated with better compliance and fewer adverse effects. Both treatment protocols failed to show an adequate eradication rate in the population of Southern Israel.

Trial registration: ClinicalTrials.gov NCT01481844.

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Fig 1. CONSORT flow diagram.
Fig 1. CONSORT flow diagram.
Fig 2. Study flow chart.
Fig 2. Study flow chart.

References

    1. Suerbaum S, Michetti P, Helicobacter pylori infection. N Engl J Med, 2002. 347(15): p. 1175–86. doi:
    1. Vergara M, Vallve M, Gisbert JP, Calvet X. Meta-analysis: comparative efficacy of different proton-pump inhibitors in triple therapy for Helicobacter pylori eradication. Aliment Pharmacol Ther, 2003. 18(6): p. 647–54.
    1. Lahaie R.G and Gaudreau C, Helicobacter pylori antibiotic resistance: trends over time. Can J Gastroenterol, 2000. 14(10): p. 895–9.
    1. Samra Z, Shmuely H, Niv Y, Dinari G, Passaro DJ, Geler A. et al., Resistance of Helicobacter pylori isolated in Israel to metronidazole, clarithromycin, tetracycline, amoxicillin and cefixime. J Antimicrob Chemother, 2002. 49(6): p. 1023–6.
    1. Thung I, Aramin H, Vavinskaya V, Gupta S, Park JY, Crowe SE. et al., Review article: the global emergence of Helicobacter pylori antibiotic resistance. Aliment Pharmacol Ther, 2016. 43(4): p. 514–33. doi:
    1. Zevit N, Levy I, Shmuely H, Samra Z, Yahav J et al., Antibiotic resistance of Helicobacter pylori in Israeli children. Scand J Gastroenterol, 2010. 45(5): p. 550–5. doi:
    1. Vakil N, H. pylori treatment: new wine in old bottles? Am J Gastroenterol, 2009. 104(1): p. 26–30. doi:
    1. Hojo M, Miwa H, Nagahara A, Sato N. Pooled analysis on the efficacy of the second-line treatment regimens for Helicobacter pylori infection. Scand J Gastroenterol, 2001. 36(7): p. 690–700.
    1. Malfertheiner P, Megraud F, O'Morain C, Bazzoli F, El-Omar E, Graham D et al., Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut, 2007. 56(6): p. 772–81. doi:
    1. Malfertheiner P, Mégraud F, O'Morain C, Hungin AP, Jones R, Axon A et al., Current concepts in the management of Helicobacter pylori infection—the Maastricht 2–2000 Consensus Report. Aliment Pharmacol Ther, 2002. 16(2): p. 167–80.
    1. Federico A, Nardone G, Gravina AG, Iovene MR, Miranda A, Compare D. et al., Efficacy of 5-day levofloxacin-containing concomitant therapy in eradication of Helicobacter pylori infection. Gastroenterology, 2012. 143(1): p. 55–61 e1; quize e13-4 doi:
    1. McNicholl AG, Marin AC, Molina-Infante J, Castro M, Barrio J, Ducons J et al., Randomised clinical trial comparing sequential and concomitant therapies for Helicobacter pylori eradication in routine clinical practice. Gut, 2014. 63(2): p. 244–9. doi:
    1. Wu DC, Hsu PI, Wu JY, Opekun AR, Kuo CH, Wu IC, et al. Sequential and concomitant therapy with four drugs is equally effective for eradication of H pylori infection. Clin Gastroenterol Hepatol, 2010. 8(1): p. 36–41 e1. doi:
    1. Gatta L, Vakil N, Leandro G, Di Mario F, Vaira D. Sequential therapy or triple therapy for Helicobacter pylori infection: systematic review and meta-analysis of randomized controlled trials in adults and children. Am J Gastroenterol, 2009. 104(12): p. 3069–79; quiz 1080. doi:
    1. Aydin A., Oruc N, Turan I, Ozutemiz O, Tuncyurek M, Musoglu A. The modified sequential treatment regimen containing levofloxacin for Helicobacter pylori eradication in Turkey. Helicobacter, 2009. 14(6): p. 520–4. doi:
    1. Graham DY, Abudayyeh S, El-Zimaity HM, Hoffman J, Reddy R, Opekun AR. Sequential therapy using high-dose esomeprazole-amoxicillin followed by gatifloxacin for Helicobacter pylori infection. Aliment Pharmacol Ther, 2006. 24(5): p. 845–50. doi:
    1. Kim SB. Lee SH, Kim KO, Jang BI, Kim TN. [Ten-day Sequential Therapy versus Bismuth Based Quadruple Therapy as Second Line Treatment for Helicobacter pylori Infection]. Korean J Gastroenterol, 2015. 66(5): p. 261–7. doi:
    1. Krystallis C., et al., A new second-line sequential regimen for Helicobacter pylori eradication based on levofloxacin: a pilot study. Dig Dis Sci, 2010. 55(12): p. 3630–1. doi:
    1. Gart JJ, Nam JM. Approximate interval estimation of the difference in binomial parameters: correction for skewness and extension to multiple tables. Biometrics. 1990. September;46(3):637–43.
    1. Gatta L, Vakil N, Vaira D, Scarpignato C. Global eradication rates for Helicobacter pylori infection: systematic review and meta-analysis of sequential therapy. BMJ, 2013. 347: p. f4587 doi:
    1. Liou J.M., Bair MJ, Chen CC, Lee YC, Chen MJ, Chen CC. et al. Levofloxacin Sequential Therapy vs Levofloxacin Triple Therapy in the Second-Line Treatment of Helicobacter pylori: A Randomized Trial. Am J Gastroenterol, 2016. 111(3): p. 381–7. doi:
    1. Nishizawa T, Suzuki H, Takahashi M, Suzuki M, Hibi T. Delay of second-line eradication therapy for Helicobacter pylori can increase eradication failure. Gastroenterol Hepatol, 2013. 28(10): p. 1608–10.
    1. Fallone CA, Chiba N, van Zanten SV, Fischbach L, Gisbert JP, Hunt RH et al., The Toronto Consensus for the Treatment of Helicobacter pylori Infection in Adults. Gastroenterology. 2016. July;151(1):51–69.e14. doi:
    1. Malfertheiner P, Megraud F, O'Morain CA, Gisbert JP, Kuipers EJ, Axon AT et al. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut. 2017. January;66(1):6–30. doi:
    1. Liou JM, Chen CC, Chen MJ, Chen CC, Chang CY, Fang YJ et al. Sequential versus triple therapy for the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial. Lancet. 2013. January 19;381(9862):205–13). doi:
    1. Draeger S, Wüppenhorst N, Kist M, Glocker EO., Outcome of second- and third-line Helicobacter pylori eradication therapies based on antimicrobial susceptibility testing. J Antimicrob Chemother, 2015. 70(11): p. 3141–5. doi:
    1. Han SR, Bhakdi S, Maeurer MJ, Schneider T, Gehring S. Stable and unstable amoxicillin resistance in Helicobacter pylori: should antibiotic resistance testing be performed prior to eradication therapy? J Clin Microbiol, 1999. 37(8): p. 2740–1.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner